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RNA interference (RNAi) is a widely used gene suppression 
tool that holds great promise as a novel antiviral approach. 
However,  for  error-prone  viruses  including  human 
immunodeficiency  virus  type  1(HIV-1),  a    combinatorial 
approach  against  multiple  conserved  sequences  is 
required  to  prevent  the  emergence  of  RNAi-resistant 
escape viruses. Previously, we constructed extended short 
hairpin RNAs (e-shRNAs) that encode two potent small 
interfering RNAs (siRNAs) (e2-shRNAs). We showed that 
a minimal hairpin stem length of 43 base pairs (bp) is 
needed to obtain two functional siRNAs. In this study, 
we elaborated on the e2-shRNA design to make e-shR-
NAs   encoding three or four antiviral siRNAs. We dem-
onstrate that siRNA   production and the antiviral effect 
is optimal for e3-shRNA of 66 bp. Further extension of 
the hairpin stem results in a loss of RNAi activity. The 
same was observed for long hairpin RNAs (lhRNAs) that 
target  consecutive  HIV-1  sequences.  Importantly,  we 
show that HIV-1 replication is durably inhibited in T cells 
stably transduced with a lentiviral vector containing the 
e3-shRNA expression cassette. These results show that 
e-shRNAs can be used as a combinatorial RNAi approach 
to target error-prone viruses.
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IntroductIon
RNA  interference  (RNAi)  is  an  evolutionarily  conserved  gene 
silencing mechanism that is induced by double-stranded RNA. 
RNAi plays an important role in the regulation of cellular gene 
expression  as  well  as  in  innate  antiviral  immune  responses.1–3 
Besides its natural functions, RNAi is widely used as a tool to 
silence  specific  genes,  with  an  associated  array  of  therapeutic 
possibilities. Transfection of plasmids that express short hairpin 
RNAs  (shRNAs)  is  commonly  used  to  induce  RNAi  in  mam-
malian  cells.4,5  Like  double-stranded  RNA,  these  shRNAs  are 
processed by the cellular Dicer endonuclease into ~22 base pairs 
(bp) small interfering RNA duplexes (siRNAs).2 One strand of the 
siRNA, the so-called “guide strand”, is incorporated into the RNA-
induced silencing complex and programs this complex to cleave 
the perfectly complementary mRNA target.6,7 The other strand of 
the siRNA, the passenger strand, is degraded.8,9
RNAi  targeted  toward  the  human  immunodeficiency  virus 
type  1  (HIV-1)  RNA  genome  via  stable  intracellular  shRNA 
expression is highly effective in suppressing viral replication.10–12 
However, the therapeutic use of a single shRNA is limited because 
of the rapid emergence of RNAi-resistant virus variants.13,14 These 
variants contain a deletion or point mutation within the   target 
sequence that abolish the antiviral effect.15,16 To reduce the chance 
of escape from RNAi attack, the virus should be targeted simul-
taneously with multiple shRNAs. There are several   combinatorial 
RNAi  strategies  to  express  multiple  effective  siRNAs.17,18  One 
can  combine  multiple  shRNA-expression  cassettes  in  a    single 
vector.19–21  Alternatively,  one  can  construct  a  microRNA-like 
polycistronic transcript that encodes multiple antiviral siRNAs.22 
Another possibility is to express long hairpin RNAs (lhRNAs), 
from which multiple siRNAs can be processed.23 Several reports 
described virus inhibition using lhRNAs against HIV-1,24–27 hepa-
titis C virus,28 and hepatitis B virus.29 In contrast to transfection 
of double-stranded RNA molecules larger than 30 bp, the intrac-
ellular expression of lhRNA at an effective dose does not readily 
induce the interferon (IFN) response.24 However, it is important 
to  note  that  even  smaller  RNA  duplexes  can  activate  the  IFN 
response in a dose-dependent manner.30,31
We previously described a set of shRNAs with potent anti-
HIV activity.19 Based on these shRNAs, we constructed extended 
shRNAs (e-shRNAs) that encode two siRNAs by stacking of the 
shRNA units on top of each other (e2-shRNAs).32 We showed that 
the siRNA derived from the base of the e2-shRNA is efficiently 
produced and fully active. However, the top siRNA was only pro-
duced when the hairpin stem reached a length of 43 bp.32 In this 
study, we designed and tested antiviral e-shRNAs that encode three 
or four siRNAs (e3 and e4-shRNAs). We show that intracellular 
expression of three appropriately stacked inhibitors as part of the 
66 bp e3-shRNA is possible without triggering the IFN response. 
Expression of longer e-shRNAs resulted in an overall reduced 
RNAi activity. We show that the RNAi activity of the e-shRNAs 
correlates with the efficiency of expression and proper intracellu-
lar processing of these transcripts into functional siRNAs. Finally, 
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we show that HIV-1 replication is durably   inhibited in T cells 
expressing  a  stably  integrated  e3-shRNA  expression  cassette. 
These results provide important insight for the design of multi-
shRNA hairpin constructs.
results
design of e-shrnAs encoding three  
and four sirnAs against HIV-1
Previously, we demonstrated that a minimal hairpin stem length 
of 43 bp is required to generate two functional siRNAs from an 
e2-shRNA.32 In an attempt to construct e-shRNAs that can   prevent 
the onset of HIV-1 escape, we designed and constructed e-shR-
NAs encoding three or four highly potent anti-HIV-1   siRNAs. 
We selected four potent antiviral shRNAs against different HIV-1 
regions: nef, pol, rev/tat (r/t), and gag (Figure 1a).19 We build 
further on the successful e2-43 hairpin design (Figure 1b), with 
shNef at the base and shPol at the top of the hairpin stem and we 
used the same expression cassette driven by the H1 polymerase III 
promoter.32 The e-shRNAs have identical 5 nucleotide (nt) loop 
sequences and the top 2 bp of the pSUPER system4 and end with 
a 3′ UU overhang derived from the polymerase III   termination 
signal. We made e-shRNA constructs that encode three siRNAs 
(e3-shRNAs) of 63 and 66 bp or four siRNAs (e4-shRNAs) of 88 
and 92 bp (Figure 1b). These length variations were tested because 
the exact cleavage sites of Dicer on these extended stems are not 
known and inappropriate processing will affect the RNAi activity. 
The additional bp between the siRNAs were obtained by   extending 
the passenger strand of the siRNA at its 3′ end with flanking 
HIV-1 derived sequences. We introduced multiple mutations in 
the passenger strand of the e-shRNA to generate relatively weak 
G-U bp in the hairpin stem (marked red in Figure 1b). We intro-
duced 3 G-U bp/shRNA unit, thus yielding a total of 9 G-U bp in 
e3-shRNA and 12 G-U bp in e4-shRNA. This G-U bp modification 
has been shown to avoid IFN induction, to improve the stability of 
the plasmid in Escherichia coli and to allow sequencing of stem-
loop structures.23,33 Importantly, introduction of G-U bp does not 
negatively affect the RNAi efficacy.33
rnAi activity of the antiviral e-shrnAs
To evaluate the suppressive activities of the novel e3 and e4-shRNA 
constructs, we co-transfected human embryonic kidney (HEK) 293T 
cells with an increasing amount of these inhibitors together with a 
fixed amount of a luciferase reporter construct with the respective 
target. As positive controls, we transfected the original shRNAs: 
shNef, shPol, shR/T, shGag, and the e2-shRNA inhibitor e2-43. As 
negative controls, we included the unrelated plasmid pBluescript 
and the control scrambled hairpin construct that harbors the scram-
bled sequence of e2-43. The renilla luciferase expression plasmid 
was included to control for transfection efficiency. Firefly and renilla 
luciferase expression was measured 2 days post-transfection and the 
ratio was used to calculate the relative luciferase activity. The firefly/
renilla ratio in the presence of pBluescript was set at 100%.
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Figure 1  design of e-shrnAs encoding 3 and 4 sirnAs. (a) The HIV-1 genome and the position of target sequences for the original 21 bp shRNAs 
(shNef, shPol, shR/T, and shGag). (b) Structure of the e2-shRNA and the e-shRNAs encoding 3 or 4 siRNAs of 63, 66, 88, or 92 bp. The e3 and e4 
constructs were made with mutations in the passenger strand of the hairpins (indicated in red), which results in destabilizing G-U bp in the hairpin 
stem. The guide strand sequences are marked in colors. bp, base pair; HIV-1, human immunodeficiency virus type 1; shRNA, short hairpin RNA; siRNA, 
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We first focus on the activity of the bottom shNef unit that 
is present in all e-shRNA designs. The e-shRNAs encoding two 
and three siRNAs (e2-43, e3-63, and e3-66) were equally active as 
the original shNef inhibitor on the Luc-nef reporter (Figure 2a). 
These results indicate that the first siRNA from the base of the 
e-shRNAs  encoding  two  and  three  siRNAs  is  produced  and 
functional. In contrast, the e4-88 and e4-92 constructs showed 
a significantly reduced inhibition of Luc-nef expression. Similar 
results were obtained when the e-shRNA constructs were tested 
on the Luc-pol reporter construct for the second shRNA unit 
(Figure 2b). Equally efficient luciferase knockdown was observed 
for e2-43 and the original shPol inhibitor, indicating that the pro-
duction of the second siRNA in this e-shRNA is equally efficient 
as in the original shRNA construct. However, the production of 
the second siRNA targeting the pol gene seems slightly impaired 
for the e3-shRNAs, e3-63 and e3-66, and even more for the e4 
constructs e4-88 and e4-92. On the Luc-r/t reporter, which was 
used to determine the activity of the third siRNA in the novel 
e-shRNAs, we observed good inhibition of luciferase expression 
by e3-63 and e3-66 that is comparable to the activity of shR/T 
(Figure 2c). In fact, e3-66 showed an increased knockdown of 
luciferase expression compared to e3-63, indicating that the addi-
tion of 3 bp improved the processing and/or activity of the top 
siRNA. Minimal knockdown of Luc-r/t expression was observed 
for the e4-88 and e4-92 constructs. We also tested the activity of 
the fourth siRNA encoded by e4-88 and e4-92 on the Luc-gag 
reporter  construct  (Figure  2d).  Consistent  with  the  previous 
results, hardly any RNAi activity was measured. These combined 
results indicate that effective e3-shRNAs can be build with a stem 
length of up to 66 bp. The addition of a fourth shRNA unit as in 
e4-88 and e4-92 has a general negative impact on all four units, 
including the shRNA at the base of the hairpin.
rnAi activity of lhrnAs with different hairpin stem 
length targeting a consecutive target sequence
To test whether the length of the hairpin stem is the cause of the 
reduced RNAi activity, we also constructed lhRNA constructs of 
66, 88, and 92 bp in size (Figure 3a). These hairpins were designed 
to contain an active siRNA sequence at the base of the hairpin, 
which is extended by adding consecutive HIV-1 sequences. We 
made two lhRNA sets with the siRNA sequence of shNef or shR/T 
at the base of the hairpin (lhNef and lhR/T). Theoretically, these 
constructs  can  produce  three  (66 bp)  and  four  (88  and  92 bp) 
siRNAs that target adjacent regions of the HIV-1 RNA genome. 
In contrast to the e-shRNA design, we only know up front that 
the siRNA at the base of the hairpin represents a potent inhibi-
tor. We again introduced point mutations in the passenger strand 
to generate G-U bp in the hairpin stem that facilitate cloning and 
sequencing (Figure 3a).
To  quantify  the  RNAi  activity  of  these  hairpins,  we  co- 
transfected HEK 293T cells with an increasing amount of lhRNA 
constructs and a fixed amount of the corresponding luciferase 
reporter. Two days post-transfection, firefly and renilla luciferase 
expression was measured and the ratio was used to calculate the 
relative luciferase activity. The RNAi activity of lhNef showed a 
slight decrease when the hairpin stem length was extended from 
66 bp to 88 or 92 bp (Figure 3b). The lhR/T showed a stronger 
reduction in luciferase knockdown with increasing stem length. 
In general, only the lhRNAs of 66 bp showed an RNAi activity that 
is comparable to that of the original shNef and shR/T inhibitors 
(Figure 3b).
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Figure 2  rnAi activity of the different sirnAs produced by   e-shrnAs. 
Luciferase reporter constructs encoding 50-nt HIV-1 sequences (a) Luc-
nef, (b) Luc-pol, (c) Luc-r/t, and (d) Luc-gag, the e-shRNA variants and 
the renilla luciferase expression plasmid (pRL) were co-transfected into 
HEK 293T cells. Two days post-transfection, firefly and renilla luciferase 
expression levels were determined and the ratio was plotted as relative 
luciferase activity. Luciferase expression in the presence of the pBS con-
trol was set at 100%. A scrambled hairpin (SCR) was used as a negative 
control and the original shRNAs (shNef, shPol, shR/T, and shGag) were 
included as positive controls. Bars represent the average values from 
five independent transfections and error bars show the SD. HEK, human 
embryonic  kidney;  HIV,  human  immunodeficiency  virus; nt,  nucle-
otide; RNAi, RNA interference; shRNA, short hairpin RNA; siRNA, small 
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To summarize the data obtained for the e-shRNA and lhRNA 
constructs, we plotted the relative luciferase activity of the base 
shRNA against the hairpin stem length (Figure 4). A general trend 
is that a reduction in RNAi activity is observed when the hairpin 
stem length exceeds 66 bp. These results suggest that there are also 
strict limitations to the length of active e-shRNAs and lhRNAs.
Inhibitory effect of each sirnA derived  
from the e-shrnAs
Several recent reports indicate that Dicer-mediated processing of 
lhRNAs may not be equal along the hairpin stem and that Dicer 
favors the production of siRNAs from the base of the hairpin 
stem.27,29,34,35 This may create a gradient of siRNA activity from the 
base (very active) to the top (poorly active). To see whether this 
also holds true for the e-shRNA design, we summarized the data 
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Figure 3  rnAi activity of lhrnAs of different hairpin stem length. (a) Design of two sets of lhRNAs targeting a consecutive sequence of the HIV-1 
nef and r/t gene of 66, 88, and 92 bp in length (lhNef and lhR/T). The shRNA targeting nef and r/t is placed at the base of the hairpin and is marked in 
green or purple, respectively. Mutations were introduced in the passenger strand of the hairpin (indicated in red) to create G-U bp in the hairpin stem 
(b) HEK 293T cells were co-transfected with the lhRNA constructs, the corresponding Luc-nef or Luc-r/t reporter and pRL. Two days post-transfection 
luciferase activities were measured and used to calculate the relative luciferase expression (firefly/renilla ratio). Luciferase expression in the presence 
of pBS was set at 100%. A scrambled hairpin (SCR) was used as negative control and the original shRNA, shNef, or shR/T, as positive control. Bars 
represent the average values from five independent transfections and error bars show the SD. bp, base pair; HEK, human embryonic kidney; lhRNA, 
long hairpin RNA; RNAi, RNA interference; shRNA, short hairpin RNA.
table 1  differential sirnA activity along the e-shrnA stem
sirnA  
position
relative luciferase  
expression (%)
construct
shrnA e2-43 e3-63 e3-66 e4-88 e4-92
Base
  Nef 4.9 4.6 8.7 8.6 44.6 47.6
  Pol 7.9 6.0 18.8 8.8 46.6 35.2
  R/T 25.5 39.7 20.7 57.2 59.5
  Gag 4.9 64.2 79.6
Top
Abbreviations: shRNA, short hairpin RNA; siRNA, small interfering RNA.
Luciferase expression without inhibitor is set at 100%.1716  www.moleculartherapy.org  vol. 17 no. 10 oct. 2009     
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obtained in the luciferase assays (Table 1). We observed similar 
knockdown efficiencies for the two siRNAs in the e2-43 hairpin 
when compared to the relative activities of the original shRNAs. 
For e3-63 and e3-66, shNef activity from the base of the hairpin was 
equal (8.7 and 8.6%, Table 1). For e3-63, we measured a gradient 
of siRNA production with the highest RNAi activity for the siRNA 
at the base and a gradual reduction in RNAi activity for the second 
and third siRNA toward the loop of the hairpin when compared 
to the shRNA controls. The optimized e3-66 construct resulted in 
enhanced activity of the second and third siRNA, resulting in a 
comparable RNAi activity as measured for the individual shRNAs. 
As already mentioned, further extension of the hairpins to 88 or 
92 bp resulted in reduced knockdown of luciferase expression. 
We observed modest RNAi activity for the first three siRNAs and 
hardly any knockdown for the fourth siRNA. Thus, we observed a 
decrease in RNAi activity from the base to the top of the hairpin, 
which is consistent with previous studies.27,29,34
Processing of e-shrnAs and lhrnAs into sirnAs
We next studied whether the differences in silencing activity of 
the units within the e-shRNA constructs correlated with their 
ability to be processed into functional siRNAs. For comparison, 
we also included the lhRNAs against nef and r/t sequences. We 
transfected HEK 293T cells with the hairpin RNA constructs and 
examined siRNA production by northern blotting. To detect siR-
NAs, we used 5′ end-labeled 19-nt locked nucleic acid probes that 
are complementary to the guide strand of the siRNA nef, pol, r/t, 
and gag.
A fair amount of fully processed siRNAs against nef, which is 
derived from the base of the e-shRNAs, was detected for e2-43, 
e3-63, and e3-66 (Figure 5, top panel). The original shNef was used 
as a positive control. A remarkable decrease in siRNA production 
was detected for the e-shRNAs encoding four siRNAs (e4-88 and 
e4-92). This result correlates well with the reduced RNAi activity 
of these constructs. A similar picture was obtained using the probe 
that detects the second siRNA against HIV-1 pol. Slightly less siR-
NAs were produced by e2-43, e3-63, e3-66 compared to the shPol 
control, but an obvious reduction in siRNA production was appar-
ent for e4-88 and e4-92. A small reduction in siRNA production 
was apparent for the e3-shRNAs compared to the e2 constructs. 
For the third siRNA R/T, a more complex picture was observed. 
The amount of siRNA produced by all e-shRNAs is much reduced 
compared to the shR/T control. Nevertheless, it is clear that e3-66 
is more efficiently processed than e3-63, e4-88, and e4-92, which is 
fully consistent with the measured RNAi activities. The gag probe 
that should detect the top siRNA of the e4-shRNAs constructs did 
not yield any signal, whereas a fair siRNA signal was detected for 
the shGag control (Figure 5, lower panel).
For the lhRNA designs targeting Nef of 66, 88, and 92 bp, we 
detected an approximate steady level of siRNA from the base of 
the hairpin (Figure 5, top panel). These results are consistent with 
the  luciferase  knockdown  experiments  in  which  we  measured 
only a slight decrease in RNAi activity when the hairpin stem 
length is extended from 66 bp to 88 or 92 bp. In contrast, the lhR-
NAs against the R/T region showed a strong reduction in siRNA 
production and RNAi activity with increasing stem length, sug-
gesting that the magnitude of activity loss due to increased stem 
length may vary for different hairpins.
the e-shrnAs and lhrnAs do not induce  
the IFn response
To test whether the e-shRNAs induce the IFN response, we per-
formed reverse transcriptase-PCR analyses for markers of the IFN 
pathway on transfected HEK 293T cells. Expression of the e3 and 
e4-shRNA constructs at the efficacious dose did not result in an 
upregulation  of  IFN-β,  2′-5′  oligoadenylate  synthase,  retinoic 
  acid-inducible gene-I, ISG56, signal transduction and activator of 
transcription-1, and myxovirus resistant gene A mRNAs in HEK 
293T cells (Figure 6a). We measured the β-actin mRNA levels 
as a control. As a positive control for IFN induction, HEK 293T 
cells were transfected with poly I:C, a synthetic double-stranded 
RNA that simulates a viral infection. Cells transfected with poly 
I:C  caused  an  upregulation  of  IFN-related  mRNAs,  indicating 
that these cells are able to activate an innate IFN response. We 
performed the same analysis for the lhNef and lhR/T constructs, 
which also did not trigger the IFN response (Figure 6b).
efficient inhibition of HIV-1 production by e3-shrnAs
Among the novel e-shRNA designs, the e3-shRNAs e3-63 and 
e3-66 showed potent RNAi activity against all three HIV-1 tar-
get sites. We next tested whether these hairpins are indeed potent 
HIV-1 inhibitors. To quantify the antiviral effects of these hair-
pins we co-transfected the HIV-1 molecular clone LAI with an 
increasing amount of e3-63 and e3-66 into HEK 293T cells. Two 
days post-transfection, capsid p24 (CA-p24) levels in the culture 
supernatant were measured as an indicator of virus production. 
CA-p24 levels were normalized to the renilla luciferase expres-
sion of the co-transfected control plasmid. Virus production in 
the presence of the empty vector was set at 100%. We measured 
a potent knockdown of HIV-1 production with e3-63 and e3-66 
(Figure 7a). At the lowest concentration, it is apparent that e3-66 
is more efficient than e3-63. These e3-shRNAs show similar or 
better inhibition of virus production than the original shRNAs. 
The scrambled hairpin that was used as a negative control was 
not able to inhibit HIV-1 production, indicating that virus sup-
pression by the e-shRNAs is sequence-specific. For the lhR/T of 
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Figure  4  rnAi  activity  of  hairpins  with  increasing  hairpin  stem 
length. The relative luciferase activity of the base shRNA of the e-shRNA 
constructs and the two lhRNA series were plotted against the hairpin 
stem length. Luciferase expression in the absence of inhibitor was set at 
100%. lhRNA, long hairpin RNA; RNAi, RNA interference; shRNA, short 
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92 bp hardly any knockdown of HIV-1 production was measured, 
providing further evidence that hairpin RNAs exceeding 66 bp are 
not efficient RNAi inducers.
To examine the potency of the e-shRNAs compared to shRNAs, 
we performed co-transfection experiments in which we carefully 
titrated  the  amount  of  hairpin  RNA  constructs  (Figure  7b). 
In general, more potent inhibition was observed for the e2 and 
e3-shRNAs compared to the individual shRNAs. In fact, the high-
est knockdown efficiency was observed for the e2-shRNA. This 
may relate to the optimal expression and silencing activity of the 
second siRNA against Pol of e2-shRNA versus both e3 constructs 
(Figures 5 and 2, respectively). However, the e3-shRNA seems 
more attractive as anti-escape therapeutic because it targets three 
different sites in the HIV-1 genome.
To  test  the  importance  of  targeting  multiple  sites  as  anti-
  escape approach, we tested the ability of the e-shRNAs to inhibit 
RNAi-escape mutants L2, L3, L6, and L7 with single or double 
point mutations in the viral target sequence (Figure 7c). Such 
mutations were previously observed in a large scale HIV-1 escape 
study.16 The three shRNA controls show the expected pattern. The 
shNef and shPol inhibitors do potently suppress production of the 
R/T-escape viruses, but the shR/T inhibitor looses its activity on 
all R/T-escape variants. The e2-shRNA does not encode siRNA 
against R/T and is thus also not sensitive to mutations in the R/T 
target. The siRNA against R/T is encoded at the top of both e3 
  constructs,  but  we  nevertheless  measured  potent  inhibition  of 
all  R/T-escape  viruses.  This  inhibition  is  obviously  due  to  the 
activity of the other two siRNA units of the e3 molecules. These 
results show the importance of targeting multiple sites to avoid the 
  emergence of viral escape.
HIV-1 replication is suppressed in cells  
expressing e3-66
To follow long-term inhibition of virus replication by the e3-66 
transcript, we transduced SupT1 T cells with a lentiviral vec-
tor (JS1) expressing the e3-66 hairpin or the control shNef. The 
titer of the e3-66 lentiviral vector was very poor, which is likely 
caused by the presence of Nef target sequences in the vector 
backbone.36 We were able to overcome this problem by satura-
tion of the RNAi machinery in the producer cell with an excess 
of unrelated shRNAs.37 Transduced SupT1 cells were selected by 
fluorescence-activated cell sorting for green fluorescent protein 
expression. The cells were subsequently expanded and infected 
with HIV-1. Cells transduced with the empty JS1 vector were 
used as a negative control. Virus replication was followed for 
49 days by monitoring the CA-p24 level in the culture superna-
tant. Virus replication and virus-induced cytopathic effects were 
observed in cells expressing the empty JS1 lentiviral vector at 
day 20 (Figure 8a, left panel). At day 35, virus replication was 
also observed in the shNef cells, however virus replication was 
not observed for the cells expressing the potent inhibitors shPol, 
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Figure  5  northern  blot  analysis  of  the  e-shrnAs  derived  sirnAs. 
Total RNA was purified from HEK 293T cells transfected with the indi-
cated e-shRNAs and lhRNAs and 10 µg was used to detect siRNAs against 
nef, pol, r/t, and gag with 19-nt complementary LNA oligonucleotide 
probes.  As  negative  controls,  the  pSUPER  vector  (ctr)  and  unrelated 
shRNAs  were  used.  The  original  shRNAs  were  used  as  positive  con-
trols, showing the processed ~22 nt siRNA. Precursor hairpin RNAs are 
indicated by asterisks. Bands that correspond to siRNAs are indicated 
by arrows. Ethidium bromide staining of the 5S rRNA band is shown 
below each panel as a control for equal sample loading. M represents 
the RNA size marker (in nt) and the probe name is indicated next to the 
blot. lhRNA, long hairpin RNA; LNA, locked nucleic acid; nt, nucleotide; 
shRNA, short hairpin RNA; siRNA, small interfering RNA.1718  www.moleculartherapy.org  vol. 17 no. 10 oct. 2009     
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shR/T, and e3-66. When we used a high amount of challenge 
virus,  we  observed  virus  replication  and  virus-induced  cyto-
pathic effects in cells expressing the empty JS1 lentiviral vector 
already at day 6 (Figure 8a, right panel). At day 16, virus replica-
tion was observed in the cells expressing shNef, whereas virus 
replication is inhibited for 49 days in the cells expressing e3-66. 
Eventually viral breakthrough occurred in these cells. The find-
ing that HIV-1 is controlled significantly longer in cells express-
ing  the  e3-66  hairpin  compared  to  those  expressing  shNef 
suggests that the second and third siRNA contribute to the virus 
inhibition by the e3-66 construct. We performed clonal sequenc-
ing of the viruses that appeared in the e3-66 expressing cells to 
determine if these represent true escape variants. The three tar-
get sequences were analyzed. We detected G-to-A mutations at 
position 8 and 13 of the Nef target (Figure 8b). In addition, one 
clone contained a big deletion of 312 nt in the Nef region, which 
includes 17 nt of the Nef target. One clone contained a T-to-C 
point mutation at position 15 in the Pol target. For the R/T target 
region we detected a single clone with an A-to-G point muta-
tion at position 13 of the target. We also detected a T-to-C point 
mutation 1 nt upstream of the target sequence.
dIscussIon
Previous studies showed that RNAi induced against HIV-1 via sta-
ble shRNA expression can efficiently suppress viral replication.10–12 
However, the impact of a single shRNA inhibitor is not sufficient, 
because of the rapid emergence of RNAi-resistant virus variants 
with a mutation in the target sequence.13–15 To prevent the onset 
of HIV-1 escape, a combinatorial RNAi approach is required in 
which  the  virus  is  targeted  simultaneously  with  multiple  siR-
NAs.  We  previously  generated  e2-shRNAs  that  encode  two 
potent   siRNAs against different HIV-1 sequences.32 Based on this 
e2-shRNA design we now build e3 and e4-shRNAs that encode 
three and four siRNAs, respectively. We included mutations in 
the passenger strand of the e3 and e4-shRNAs to obtain relatively 
unstable G-U bp in the hairpin. This G-U design facilitates cloning 
and sequencing of the hairpin encoding inverted repeats, without 
negatively affecting the hairpin’s RNAi activity.23,33
We showed that the e4-shRNAs have reduced RNAi activity 
compared to the e3-shRNAs. The same length effect was observed 
for lhRNAs that target a consecutive viral target sequence. In agree-
ment with our results, previous reports also suggested that hair-
pin transcripts have an upper size limit for effective production 
of multiple, functional siRNAs.27,34 In general, the hairpins seem 
to lose activity when they get larger than ~66 bp. Northern blot 
analyses showed a coinciding decrease in siRNA production from 
the e4-shRNAs. This decrease in siRNA production could be due 
to reduced e4-shRNA expression, diminished stability, hampered 
nuclear export, or poor processing into functional siRNAs. In the 
latter case, more precursor transcripts or intermediately processed 
products should have been observed on northern blot, which was 
not the case. These combined results indicate that the reduced 
RNAi activity of the e4-shRNAs is due to diminished expression 
and/or stability. Diminished expression of the lhRNA transcripts 
could be related to the use of the H1 pol III promoter. It could be 
that the e4-88 (~187 nt) and e4-92 (~195 nt) hairpin transcripts 
are less efficiently transcribed by this promoter. In this case, other 
promoters could be tested, for example: the strong and ubiquitous 
pol II promoter of the human U1 small nuclear RNA.20,38
Another  possibility  for  the  inactivity  of  the  e4-transcripts 
is that the wrong strand of the siRNA, the passenger strand, is 
selected for incorporation into the RNA-induced silencing com-
plex. To test this, we performed northern blot analyses with probes 
that detect the passenger strand, but did not detect increased pas-
senger strand expression for the e4-shRNAs compared to the e2 
and e3-shRNAs (results not shown).
We succeeded to generate an e3-66 molecule that produces 
three active siRNAs, where our previous hairpin stacking attempts 
stopped at two siRNAs.32 By size optimization, more specifically 
the addition of 3 bp to e3-63, the processing of the top siRNA 
was activated in e3-66. We observed a gradient of siRNA produc-
tion from the base toward the top of the hairpin. We compared 
the potency of the e-shRNAs compared to the shRNAs to inhibit 
HIV-1 production. In general, we observed more potent inhibition 
for the e2 and e3-shRNAs than the individual shRNAs. Overall, 
we measured optimal HIV-1 inhibitory activity of the e2 design, 
but the advantage of e3 molecules against an evolving viral target 
is that the selection of escape-variants is more difficult. For RNAi 
inhibition of static cellular mRNAs, the e2 design seems optimal. 
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Figure 6  the e-shrnA and lhrnA transcripts do not induce the inter-
feron response. Total RNA was purified from HEK 293T cells transfected 
with (a) e-shRNAs and (b) lhRNAs at an efficacious dose. The IFN-β, 
OAS, RIG-I, ISG56, STAT-1, and MxA expression levels were determined 
by RT-PCR. β-actin mRNA expression serves as an internal control. We 
included poly I:C transfected cells as positive control. As negative controls, 
cells were Mock transfected or with the pSUPER vector (ctr). We also per-
formed a control PCR on RNA extracts derived from poly I:C transfected 
cells that were not subjected to reverse transcription. Either the 200 or 
400 bp lane of the SmartLadder (M) (Eurogentec) is shown as size refer-
ence. HEK, human embryonic kidney; IFN-β, interferon-β; lhRNA, long 
hairpin RNA; MxA, myxovirus resistant gene A; OAS, 2′-5′ oligoadenylate 
synthase; RIG-I, retinoic acid-inducible gene-I; shRNA, short hairpin RNA; 
STAT-1, signal transduction and activator of transcription-1.Molecular Therapy  vol. 17 no. 10 oct. 2009  1719
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In case an even more complete gene knockdown is required, it 
would seem preferential to use two e2 molecules in a combinato-
rial RNAi approach.17,18
We previously showed that combinatorial RNAi using four 
separate  shRNA  expression  cassettes  efficiently  prevents  the 
chance  of  HIV-1  escape  from  RNAi.20  This  approach  requires 
the use of different pol III promoters to prevent the loss of indi-
vidual shRNA expression cassettes from the lentiviral vector via 
homologous recombination. The e-shRNA design aimed to pro-
vide combinatorial RNAi from a single expression cassette. HIV-1 
replication is suppressed for >7 weeks in cells that stably express 
the e3-66 hairpin, whereas viral breakthrough is readily apparent 
for the single shNef control. Nevertheless, virus replication was 
observed in the cells expressing e3-66 when a high amount of 
challenge virus was used. These results illustrate the effectiveness 
of the e3-shRNA design in providing durable HIV-1 inhibition 
compared to the shNef. These data indicate that the expression 
of the second and third siRNA from the e3-66 hairpin does sig-
nificantly contribute to the observed virus inhibition. To further 
optimize the e3-66 hairpin design, we should place a more potent 
shRNA at the base of the hairpin since shNef is at most a mod-
est inhibitor. An important advantage of the e3-shRNA design is 
that it causes only a modest reduction in the lentiviral vector titer, 
whereas the titer of the four shRNA vector is much reduced.20 The 
ability to obtain high lentiviral vector titers is critical for the clini-
cal development of a gene therapy.
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Figure 7  Inhibition of wild-type and mutant HIV-1 variants by e-shrnAs. (a) HEK 293T cells were co-transfected with the HIV-1 molecular clone 
pLAI, pRL, and increasing amounts of e3-shRNA constructs. Two days post-transfection, HIV-1 production was measured by CA-p24 quantification 
in the culture supernatant. CA-p24 levels were normalized for renilla expression; virus production with the pSUPER vector (ctr) was set at 100%. The 
original shRNAs were used as positive controls. The SCR served as negative control. (b) Inhibition of HIV-1 production by e-shRNAs at low concen-
trations. Transfections were performed as described for a, but now including the e2 design and we used reduced shRNA concentrations to carefully 
examine their potency. The SCR and pBS served as negative control. (c) Inhibition of RNAi-escape viruses by e-shRNAs. Sequence of the L2, L3, L6, 
and L7 HIV-1 variants that contain mutations in the R/T siRNA target region. Inhibition of CA-p24 expression was determined as described above. The 
mean values and standard deviations are based on three independent experiments. HEK, human embryonic kidney; HIV, human immunodeficiency 
virus; RNAi, RNA interference; SCR, scrambled hairpin; shRNA, short hairpin RNA.1720  www.moleculartherapy.org  vol. 17 no. 10 oct. 2009     
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We performed clonal sequencing of the viruses that appeared in 
the e3-66 expressing cells to determine whether genetic alterations 
were selected in the target sequences. We found point mutations and 
a gross deletion in the Nef target sequence. These genetic alterations 
likely do not impact on virus replication because the Nef protein is 
not required for viral replication in vitro. In addition, we found a 
silent point mutation in the Pol target that has also been detected 
as a popular escape route in a large-scale evolution study.16 We also 
detected point mutations in the R/T target. One mutation is in fact 
positioned 1 nt upstream of the R/T target, suggesting that siRNAs 
of variable lengths are generated. Another mutation was located in 
the target region and was also previously described as escape route, 
although this mutation causes an amino acid change in both the Tat 
and Rev proteins.16 It is important to notice that we only observed 
scattered escape mutations, as none of them became dominant in 
the viral quasispecies. These results indicate that it is difficult for the 
virus to develop full resistance to the e3-shRNA.
Besides escape, another major challenge toward an effective 
anti-HIV therapy is the need to target the vast number of dif-
ferent virus variants that are present in the epidemic and in an 
infected individual. Multiple e2 or e3-shRNA expression cassettes 
may provide the profound and broad inhibition that is required to 
simultaneously block different HIV-1 variants. Another possibility 
is to use multiple e3-shRNA expression cassettes to target HIV-1 
and cellular cofactors, which may result in an even more potent 
and durable inhibition. An adverse effect of this approach is the 
increased chance of off-target effects or saturation of the RNAi 
machinery. Future experiments in an appropriate in vivo model 
should reveal whether multiple e-shRNAs can provide durable 
HIV inhibition without toxicity.39
In conclusion, we showed that stacked e-shRNA constructs have 
potential for long-term inhibition of HIV-1 replication. However, 
there is an upper size limit such that maximally three siRNAs can 
be generated from a single e-shRNA. Moreover, we showed that a 
gradient of siRNA activity is observed along the hairpin stem, with 
the most efficiently expressed siRNA from the base of the hairpin. 
Importantly,  we  demonstrated  that  HIV-1  replication  is  dura-
bly inhibited in T cells expressing a stably integrated e3-shRNA 
expression cassette. These results provide important insights for 
the use of e-shRNAs for a durable inhibition of escape-prone viral 
pathogens. In addition, the e-shRNA design may present a useful 
new research tool for the knockdown of multiple genes.
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MAterIAls And MetHods
DNA  constructs.  The  e-shRNA  constructs  were  made  by  annealing  of 
  complementary oligonucleotides (containing the BamHI and HindIII sites) 
and inserting them into the BglII and HindIII sites of the pSUPER vector.4 
The lhRNAs targeting the nef and r/t region were made by PCR amplifica-
tion of the guide strand of the hairpin RNA with a primer including the 5-nt 
loop sequences and top 2 bp of the pSUPER system. The passenger strand 
of the hairpin RNA was made by annealing oligonucleotides containing the 
loop and some additional nucleotides that are complementary to the guide 
strand of the hairpin. The passenger and guide strand of the hairpin was 
combined by a fusion PCR with primers containing the BamHI and HindIII 
sites. The PCR products were purified from agarose gels and digested with 
BamHI and HindIII and inserted into the BglII and HindIII sites of the 
  pSUPER vector. The 43 bp control scrambled hairpin construct encodes the 
scrambled sequence of e2-43 and has been described   previously.32 The con-
struct expressing the 5xshRNA Gag5, Pol1, Pol6, Pol9, Pol47 from repeated 
H1 promoters was constructed as described previously.40
The pLAI plasmid encoding the HIV-1 isolate LAI41 was used to study 
inhibition of HIV-1 production. For the R/T mutants, a single mutation 
was introduced at position 11 for L2 and position 6 for L7 and double 
mutations were introduced at position 8/11 and 13/15 in the target sequence 
for L3 and L6, respectively. Such mutations have been previously observed 
in a large scale HIV-1 RNAi-escape study.16 Mutations were introduced by 
fusion PCR using oligonucleotides with the desired mutations.
Firefly luciferase reporter constructs (pGL3; Promega, Madison, WI): 
Luc-nef, Luc-pol, Luc-r/t, and Luc-gag were made by insertion of a 50–70-
nt HIV-1 sequence, with the 19-nt target region in the centre, in the EcoRI 
and PstI sites of pGL3-Nef.15,19,20
Lentiviral vector plasmids are derived from the construct (pRRL-
cpptpgkgfppreSsin),42 which we renamed as JS1. The plasmids JS1-shNef, 
JS1-shPol, JS1-shR/T and JS1-e3-66 were obtained by digestion of the 
pSUPER construct with XhoI and PstI and inserting this fragment into 
the corresponding sites of JS1.
All DNA constructs were sequence verified using the BigDye terminator 
cycle sequencing kit (ABI, Foster City, CA). Hairpin RNA constructs were 
sequenced using a sample denaturation temperature of 98 °C and upon 
addition of 1 mol/l betaine. We used the Mfold program to calculate the 
thermodynamic stability of the RNA secondary structure of the antiviral 
transcripts.43
Cell culture, transfections, and virus infection. HEK 293T cell line was cul-
tured in Dulbecco’s modified Eagle’s medium (DMEM; Invitrogen, Carlsbad, 
CA) supplemented with 10% fetal calf serum (FCS) (Hybond, Escondido, 
CA), penicillin (100 U/ml), streptomycin (100 μg/ml), and minimal essen-
tial medium nonessential amino acids (DMEM/10% FCS) at 37 °C and 5% 
CO2. For luciferase assays, HIV-1 inhibition assays and the IFN assay, HEK 
293T cells were plated 1 day before transfection in 24-well plates at a density 
of 1.4 × 105 cells/well in 1 ml DMEM/10% FCS without anti  biotics. Cells 
were transfected with Lipofectamine 2000 reagent (Invitrogen) according to 
the manufacturer’s instructions. Transfection experiments were corrected 
for between-session variation as described previously.44
For  siRNA  analysis,  HEK  293T  cells  were  plated  1  day  before 
transfection in 6-well plates at a density of 6.0 × 105 cells/well in 2 ml 
DMEM/10% FCS without antibiotics. The next day, cells were transfected 
with 5 µg of the hairpin RNA constructs with Lipofectamine 2000 reagent 
(Invitrogen) as suggested by the manufacturer.
The human T-cell line SupT1 was cultured in Advanced RPMI (Gibco 
BRL, Carlsbad, CA) supplemented with l-glutamine, 1% FCS, penicillin 
(30 U/ml), and streptomycin (30 μg/ml) at 37 °C and 5% CO2. SupT1 cells 
(200.000) were infected with HIV-1 (0.03 or 0.001 ng CA-p24) produced 
in HEK 293T cells. When HIV-induced cytopathic effects were observed, 
cell and supernatant samples were stored at −80 °C. Virus spread was 
followed by measuring the CA-p24 levels in the culture supernatant by 
enzyme-linked immunosorbent assay.
Luciferase assays. HEK 293T cells were co-transfected with 100 ng of the 
firefly luciferase expression plasmid, 1 ng of renilla luciferase expression 
plasmid (pRL-CMV) and 5, 25, or 100 ng of hairpin RNA expression con-
structs. We added pBluescript SK-(pBS) (Promega) to all transfections to 
obtain equal DNA concentrations. Two days post-transfection, firefly and 
renilla luciferase activities were assessed using the Dual-luciferase Reporter 
Assay  System  (Promega)  according  to  the  manufacturer’s  instructions. 
Relative luciferase activities were calculated from the ratio between firefly 
and renilla luciferase activities. Transfection experiments were corrected 
for between-session variation as described previously.44
HIV-1 inhibition assay. HEK 293T cells were co-transfected with 250 ng of 
the HIV-1 infectious molecular clone pLAI, 1 ng of pRL-CMV and 1.25, 
2.5, 5, 10, 20, or 25 ng of the hairpin RNA constructs. We added pBluescript 
to obtain an equal DNA concentration in each transfection. To determine 
inhibition of the RNAi-escape variants L2, L3, L6, and L7, 250 ng of the 
molecular clones were co-transfected with 1 ng of pRL-CMV and 10 ng of 
the e-shRNA constructs. Virus production was determined at 2 days post-
transfection by measuring the CA-p24 level in the culture supernatant 
by enzyme-linked immunosorbent assay as described previously.45 Cells 
were lysed and 5 µl of the lysate was used to measure the renilla luciferase 
activities using the Renilla Luciferase Assay System (Promega). The relative 
CA-p24 production was calculated as the quotient between the CA-p24 
level and the renilla luciferase activity, which was corrected for between-
session variation.44
Northern  blot  analyses. Total cellular RNA was extracted from trans-
fected  HEK  293T  cells  at  2  days  post-transfection  using  the  mirVana   
microRNA isolation kit (Invitrogen) according to the manufacturer’s pro-
tocol. For northern blot analysis, 10 µg of total RNA per lane was resolved 
on urea denaturing 15% polyacrylamide gel (Invitrogen). RNA molecular 
weight markers (Ambion, Foster City, CA) were prepared as suggested by 
the manufacturer’s protocol and run alongside the cellular RNA. To check 
for equal sample loading, ribosomal RNA in the gel was stained with 2 µg/  ml 
ethidium bromide for 20 minutes. Destaining was performed by rinsing the 
gel three times with milliQ water for 10 minutes. The ribosomal RNA bands 
were visualized under ultraviolet light. The RNA samples in the gel were 
electrotransferred to a positively charged nylon membrane (Boehringer 
Mannheim,  Mannheim,  Germany)  and  crosslinked  to  the  membrane 
using ultraviolet light at a wavelength of 254 nm (1,200 µJ × 100). Locked 
nucleic acid oligonucleotide probes were 5′ end labeled with the kinase-
Max kit (Ambion) in the presence of 1 µl of [γ-32P]adenosine triphosphate 
(0.37 MBq/µl; Perkin Elmer, Waltham, MA). The probes were purified on 
Sephadex G-25 spin columns (Amersham Biosciences, Piscataway, NJ) to 
remove unincorporated nucleotides. Hybridizations were performed with 
labeled locked nucleic acid oligonucleotides in 10 ml ULTRAhyb hybrid-
ization buffer (Ambion) at 42 °C according to the manufacturer’s instruc-
tions.  We  used  oligonucleotide  probes  (locked  nucleic  acid-positions 
underlined): nef probe: 5′ GGGACTGGAAGGGCTAATT 3′, pol probe: 
5′ ACAGGAGCAGATGATACAG 3′, r/t probe: 5′ ATGGCAGGAAGAAGC 
GGAG 3′, gag probe: 5′ GAAGAAATGATGACAGCAT 3′. After overnight 
hybridization, the membranes were washed twice for 5 minutes at 42 °C in 
2 × SSC/0.1% sodium dodecyl sulfate and twice for 15 minutes at 42 °C 
in 0.1 × SSC/0.1% sodium dodecyl sulfate. Signals were detected using a 
phosphorimager (Amersham Biosciences).
IFN assay. To determine whether the extended hairpin RNA constructs 
induce  the  IFN  pathway  at  their  efficacious  dose,  HEK  293T  cells 
were  transfected  with  25 ng  of  the  hairpin  encoding  constructs  using 
Lipofectamine 2000 reagent (Invitrogen). Transfection of 2 μg poly I:C 
was used as a positive control for IFN-β induction as described previous-
ly.24 Total RNA was isolated from cells 1 day post-transfection using the 
RNeasy mini kit (Invitrogen) according to the manufacturer’s   protocol. 
Genomic  DNA  was  removed  by  DNase  treatment  using  the  TURBO 1722  www.moleculartherapy.org  vol. 17 no. 10 oct. 2009     
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DNA-free kit (Ambion). One microgram of total RNA, Thermoscript 
RT (Invitrogen) and random hexamer primers (Invitrogen) were used to 
reverse transcribe the RNA into complementary DNA according to the 
manufacturer’s instructions (Invitrogen).
PCR  amplification  was  performed  on  2 µl  of  this  complementary 
DNA-containing  mixture  with  IFN-β,  2′-5′  oligoadenylate  synthases, 
retinoic acid-inducible gene-I, ISG56, signal transduction and activator of 
transcription-1, myxovirus resistant gene A, and β-actin specific primers. 
The following primer combinations were used:
IFN-β, f: 5′-GCCGCATTGACCATCTATGAGA-′3; r: 5′-GAGATC 
TTCAGTTTCGGAGGTAAC-′3  (345 bp  product),  2′-5′  oligoadenylate 
synthase,  f:  5′-TCAGAAGAGAAGCCAACGTGA-′3;  r:  5′-CGGAGAC 
AGCGAGGGTAAAT-′3  (399 bp  product),46  retinoic  acid-inducible 
gene-I, f: 5′-GAGTGTCTTTTCTTATGTGATTTT-′3; r: 5′-GCAGGCAA 
GTCTTACATGGCAGCA-′3 (268 bp product), ISG56, f: 5′-CTTGAGCC 
TCCTTGGGTTCG-′3;  r:  5′-GCTGATATCTGGGTGCCTAAGG-′3 
(137 bp product),47 signal transduction and activator of transcription-1, 
f: 5′-TTCTGTGTCTGAAGTGTAAGTGAA-′3; r: 5′-TAACACGGGGAT 
CTCAACAAGTTC-′3 (159 bp product), myxovirus resistant gene A, f: 5′- 
AGTATGGTGTCGACATACCGGA-′3; r: 5′-GAGTCTGGTAAACAGCC 
GAATG-′3 (145 bp product),47 β-actin f: 5′-GACTACCTCATGAAGATCC 
TCAC-3′; r: 5′-ATTGCCAATGGTGATGACCTG-3′ (197 bp product).
For PCR amplification, the Reddymix Master Mix (Abgene, Epsom, 
UK) was used in a 50 µl reaction using the following PCR program: 3 
minutes at 95 °C, 30 cycles of 30 seconds at 95 °C, 30 seconds at 57 °C, 
45 seconds at 72 °C and a final extension for 8 minutes at 72 °C. The PCR 
products  were  analyzed  on  a  1.5%  agarose  gel  with  the  SmartLadder 
(Eurogentec, San Diego, CA) as a size reference.
Lentiviral vector production and transduction. Lentiviral vector plas-
mids are derived from the construct JS1 (pRRLcpptpgkgfppreSsin).42 For 
production of lentiviral vector, 6.0 × 105 HEK 293T cells were seeded per 
well in 6-well plates in 4 ml of DMEM/10% FCS without antibiotics. The 
next day, medium was replaced with 0.4 ml medium without antibiotics. 
Subsequently, the empty JS1 vector and JS1 vectors expressing shNef, 
shPol, shR/T and e3-66 (0.95 µg) were co-transfected with packaging 
plasmids pSYNGP (0.6 µg),48 RSV-rev (0.25 µg), pVSVg (0.33 µg),49 and 
a 5 shRNA-expressing construct, p5xshRNA (2.9 µg) with Lipofectamine 
2000 reagent in accordance with the manufacturer’s recommendations 
(Invitrogen). The second day, medium was replaced with 1 ml optimem. 
On the third day, medium containing lentiviral vector was harvested. 
Cellular debris was removed by centrifugation for 5 minutes at 1,200 
r.p.m. Lentiviral stocks were titrated on SupT1 cells to determine the 
vector titer. SupT1 cells were transduced with the lentiviral vectors at 
a multiplicity of infection of 0.15 as described previously.19 Four days 
post-transduction, live transduced cells were sorted with fluorescence-
activated cell sorting and single green fluorescent   protein-positive cells 
were selected. Sorted cells were expanded and resorted at 30 days post-
transduction. These cells were used to determine long-term inhibition 
of HIV-1 replication.
Sequencing  proviral  target  regions. Cellular DNA of infected SupT1 
cells with the integrated provirus was isolated as described previously.50  
Integrated  proviral  DNA  sequences  were  PCR  amplified  with  the   
following primer pairs (indicated 5′-3′). Nef region, forward: ATTCG 
CCACATACCTAGAAG,  reverse:  GACTCTGGTAACTAGAGATCCC 
TCAGACC;  Pol  region,  forward:  AGGCTAATTTTTTAGGGAAGA 
TCTGGCCTTCC,  reverse:  GCAAATACTGGAGTATTGTATGGATT 
TTCAGG and R/T region, forward: ACCTTGTCTAGAATGGAGCCAG 
TAGATCCTAGACTAGAGCCCTG,  reverse:  TTCCACACAGGTA 
CCCCATAATAGACTGTGACCCACA. The PCR products were cloned 
into the pCR2.1 TOPO vector and subsequently clones were sequenced 
with the T7 or M13 reverse primers.
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